Literature DB >> 11894982

Malignant thymic carcinoid is not prevented by transcervical thymectomy in multiple endocrine neoplasia type 1.

J R Burgess1, N Giles, J J Shepherd.   

Abstract

Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal dominant tumour syndrome. It is characterized by primary hyperparathyroidism, pituitary neoplasia and foregut lineage neuroendocrine neoplasia. Malignant thymic carcinoid tumours are an uncommon but important manifestation of MEN 1. Transcervical thymectomy is often advocated as prophylaxis against thymic carcinoids, although there is a paucity of evidence to support the efficacy of this procedure. This is the first report of a malignant thymic carcinoid occurring in an MEN 1 patient following prior parathyroidectomy and transcervical thymectomy. It is concluded that transcervical thymectomy does not reliably provide prophylaxis against thymic carcinoid.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11894982     DOI: 10.1046/j.1365-2265.2001.01348.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

Review 1.  Somatostatin receptor scintigraphy in thoracic diseases.

Authors:  P Ameri; F Gatto; M Arvigo; G Villa; E Resmini; F Minuto; G Murialdo; D Ferone
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

Review 2.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 3.  Care for patients with multiple endocrine neoplasia type 1: the current evidence base.

Authors:  C R C Pieterman; M R Vriens; K M A Dreijerink; R B van der Luijt; G D Valk
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

4.  The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism.

Authors:  Anathea C Powell; H Richard Alexander; James F Pingpank; Seth M Steinberg; Monica Skarulis; David L Bartlett; Sunita Agarwal; Craig Cochran; Geoffrey Seidel; Douglas Fraker; Marybeth S Hughes; Robert T Jensen; Stephen J Marx; Steven K Libutti
Journal:  Surgery       Date:  2008-12       Impact factor: 3.982

Review 5.  Endocrine neoplasms in familial syndromes of hyperparathyroidism.

Authors:  Yulong Li; William F Simonds
Journal:  Endocr Relat Cancer       Date:  2016-05-20       Impact factor: 5.678

6.  Atypical thymic carcinoid in multiple endocrine neoplasia type 1 syndrome.

Authors:  A Vidal; M J Lorenzo; M L Isidro; F Cordido
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

7.  Surgical approach to the patient with familial hyperparathyroidism.

Authors:  Lindi H VanderWalde; Philip I Haigh
Journal:  Curr Treat Options Oncol       Date:  2006-07

Review 8.  Gender Differences in Multiple Endocrine Neoplasia Type 1: Implications for Screening?

Authors:  Jerena Manoharan; Carmen Bollmann; Peter Herbert Kann; Pietro Di Fazio; Detlef K Bartsch; Max B Albers
Journal:  Visc Med       Date:  2020-01-24

Review 9.  Total parathyroidectomy in a large cohort of cases with hyperparathyroidism associated with multiple endocrine neoplasia type 1: experience from a single academic center.

Authors:  Fabio Luiz de Menezes Montenegro; Delmar Muniz Lourenço; Marcos Roberto Tavares; Sergio Samir Arap; Climerio Pereira Nascimento; Ledo Mazzei Massoni Neto; André D'Alessandro; Rodrigo Almeida Toledo; Flávia Lima Coutinho; Lenine Garcia Brandão; Gilberto de Britto e Silva Filho; Anói Castro Cordeiro; Sergio Pereira Almeida Toledo
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

10.  Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Marc J Berna; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2013-05       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.